{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:44:16Z","timestamp":1787003056241,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy in patients aged 70\u201380 years. In this prespecified translational analysis (Trans-RESPECT), HER2DX scores were available for 154 patients. The HER2DX\u00a0risk score classified 74.0% as low risk and 26.0% as high risk. Ten-year relapse-free and overall survival were higher in the low-risk group. HER2DX remained independently associated with overall survival in multivariable analysis. The HER2DX immune, luminal, and proliferation signatures that compose the risk score were also prognostic. While the HER2DX pCR score was not prognostic overall, exploratory subgroup analyses suggested a potential survival benefit from chemotherapy in the pCR-high group. HER2DX offers prognostic value and may guide chemotherapy use in older patients with HER2-positive early breast cancer.\n                    <jats:bold>Clinical Trial Information<\/jats:bold>\n                    NCT01104935\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-65599-x","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:03:35Z","timestamp":1762250615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab \u00b1 chemotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Kazuki","family":"Nozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Tsuneizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Gondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikata","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Harao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-7795","authenticated-orcid":false,"given":"Tatsuya","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-6512","authenticated-orcid":false,"given":"Ana","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Perou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4707-9803","authenticated-orcid":false,"given":"Wesley","family":"Buckingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Mar\u00edn-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"65599_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"65599_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","volume":"21","author":"AG Waks","year":"2024","unstructured":"Waks, A. G. et al. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nat. Rev. Clin. Oncol. 21, 818\u2013832 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65599_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ctrv.2003.12.001","volume":"30","author":"H Wildiers","year":"2004","unstructured":"Wildiers, H. & Paridaens, R. Taxanes in elderly breast cancer patients. Cancer Treat. Rev. 30, 333\u2013342 (2004).","journal-title":"Cancer Treat. Rev."},{"key":"65599_CR4","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","volume":"25","author":"HB Muss","year":"2007","unstructured":"Muss, H. B. et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J. Clin. Oncol. 25, 3699\u20133704 (2007).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.20.02063","volume":"39","author":"A Magnuson","year":"2021","unstructured":"Magnuson, A. et al. Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer. J. Clin. Oncol. 39, 608\u2013618 (2021).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR6","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1200\/JCO.20.02329","volume":"38","author":"de Azambuja","year":"2020","unstructured":"de Azambuja et al. Are we RESPECTing older patients with breast cancer?. J. Clin. Oncol. 38, 3727\u20133730 (2020).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR7","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics 2024. CA A Cancer J. Clinicians 74, 477\u2013495 (2024).","journal-title":"CA A Cancer J. Clinicians"},{"key":"65599_CR8","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1200\/JCO.2003.09.124","volume":"21","author":"MM Kemeny","year":"2003","unstructured":"Kemeny, M. M. et al. Barriers to clinical trial participation by older women with breast cancer. J. Clin. Oncol. 21, 2268\u20132275 (2003).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR9","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","volume":"38","author":"M Sawaki","year":"2020","unstructured":"Sawaki, M. et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J. Clin. Oncol. 38, 3743\u20133752 (2020).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2023.0187","volume":"9","author":"C Bueno-Mui\u00f1o","year":"2023","unstructured":"Bueno-Mui\u00f1o, C. et al. Assessment of a genomic assay in patients with ERBB2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. JAMA Oncol. 9, 841\u2013846 (2023).","journal-title":"JAMA Oncol."},{"key":"65599_CR11","doi-asserted-by":"crossref","unstructured":"Guarneri, V. et al. HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial. eBioMedicine 85, 104320 (2022).","DOI":"10.1016\/j.ebiom.2022.104320"},{"key":"65599_CR12","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-24-0464","volume":"30","author":"A Llombart-Cussac","year":"2024","unstructured":"Llombart-Cussac, A. et al. HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from PHERGain phase II trial. Clin. Cancer Res. 30, 4123\u20134130 (2024).","journal-title":"Clin. Cancer Res."},{"key":"65599_CR13","doi-asserted-by":"crossref","unstructured":"Mar\u00edn-Aguilera, M. et al. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer. ESMO Open 9, 102903 (2024).","DOI":"10.1016\/j.esmoop.2024.102903"},{"key":"65599_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.  Lancet Oncol. 21, 1455\u20131464 (2020).","journal-title":"Lancet Oncol."},{"key":"65599_CR15","doi-asserted-by":"crossref","unstructured":"Prat, A. et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. eBioMedicine 75, 103801 (2022).","DOI":"10.1016\/j.ebiom.2021.103801"},{"key":"65599_CR16","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.02170","volume":"42","author":"P Tarantino","year":"2024","unstructured":"Tarantino, P. et al. Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2\u2013positive breast cancer: 5-year results and correlative analyses from ATEMPT. J. Clin. Oncol. 42, 3652\u20133665 (2024).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","volume":"24","author":"SM Tolaney","year":"2023","unstructured":"Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.  Lancet Oncol. 24, 273\u2013285 (2023).","journal-title":"Lancet Oncol."},{"key":"65599_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103987","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney, S. M. et al. HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open 9, 103987 (2024).","journal-title":"ESMO Open"},{"key":"65599_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102388","volume":"9","author":"G Villacampa","year":"2024","unstructured":"Villacampa, G. et al. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network Breast dataset (SCAN-B). ESMO Open 9, 102388 (2024).","journal-title":"ESMO Open"},{"key":"65599_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","volume":"34","author":"G Villacampa","year":"2023","unstructured":"Villacampa, G. et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann. Oncol. 34, 783\u2013795 (2023).","journal-title":"Ann. Oncol."},{"key":"65599_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaoncol.2023.0181","volume":"9","author":"AG Waks","year":"2023","unstructured":"Waks, A. G. et al. Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. JAMA Oncol. 9, 835\u2013840 (2023).","journal-title":"JAMA Oncol."},{"key":"65599_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 372, 134\u2013141 (2015).","journal-title":"N. Engl. J. Med."},{"key":"65599_CR23","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.20.03398","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney, S. M. et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J. Clin. Oncol. 39, 2375\u20132385 (2021).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR24","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-S\u00e1ez, O. et al. Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study. ESMO Real World Data Digital Oncol. 8, 100123 (2025).","DOI":"10.1016\/j.esmorw.2025.100123"},{"key":"65599_CR25","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s12094-023-03215-4","volume":"25","author":"F Ayala de la Pe\u00f1a","year":"2023","unstructured":"Ayala de la Pe\u00f1a, F. et al. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clin. Transl. Oncol. 25, 2647\u20132664 (2023).","journal-title":"Clin. Transl. Oncol."},{"key":"65599_CR26","doi-asserted-by":"publisher","unstructured":"Burstein H. J. et al. Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.007 (2025).","DOI":"10.1016\/j.annonc.2025.09.007"},{"key":"65599_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-4-3","volume":"4","author":"C Fan","year":"2011","unstructured":"Fan, C. et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med. Genomics 4, 3 (2011).","journal-title":"BMC Med. Genomics"},{"key":"65599_CR28","first-page":"78","volume":"71","author":"MS Sedrak","year":"2021","unstructured":"Sedrak, M. S. et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J. Clinicians 71, 78\u201392 (2021).","journal-title":"CA Cancer J. Clinicians"},{"key":"65599_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jgo.2016.11.001","volume":"8","author":"H Singh","year":"2017","unstructured":"Singh, H., Beaver, J. A., Kim, G. & Pazdur, R. Enrollment of older adults on oncology trials: an FDA perspective. J. Geriatr. Oncol. 8, 149\u2013150 (2017).","journal-title":"J. Geriatr. Oncol."},{"key":"65599_CR30","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","volume":"22","author":"L Biganzoli","year":"2021","unstructured":"Biganzoli, L. et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).  Lancet Oncol. 22, e327\u2013e340 (2021).","journal-title":"Lancet Oncol."},{"key":"65599_CR31","unstructured":"(BIG) BIG. Research in Focus: Unmet Needs of Older People (Breast International Group (BIG), 2022)."},{"key":"65599_CR32","unstructured":"Services UDoHaH. Food and Drug Administration. Inclusion of Older Adults in Cancer Clinical Trials: Guidance for Industry (FDA, 2022). Available at https:\/\/www.fda.gov\/media\/156616\/download."},{"key":"65599_CR33","doi-asserted-by":"crossref","unstructured":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 115-year survival: an overview of the randomised trials. The Lancet 365, 1687\u20131717 (2005).","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"65599_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(25)00832-3","volume":"406","author":"E Brain","year":"2025","unstructured":"Brain, E. et al. Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.  Lancet 406, 489\u2013500 (2025).","journal-title":"Lancet"},{"key":"65599_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clbc.2023.03.007","volume":"23","author":"J O\u2019Shaughnessy","year":"2023","unstructured":"O\u2019Shaughnessy, J., Gradishar, W., O\u2019Regan, R. & Gadi, V. Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin. Breast Cancer 23, 350\u2013362 (2023).","journal-title":"Clin. Breast Cancer"},{"key":"65599_CR36","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","volume":"26","author":"G Villacampa","year":"2025","unstructured":"Villacampa, G. et al. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis of 2,518 patients from eleven studies. Lancet Oncol. 26, 1100\u20131112 (2025).","journal-title":"Lancet Oncol."},{"key":"65599_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl, S. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 159\u2013182 (2024).","journal-title":"Ann. Oncol."},{"key":"65599_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer","year":"2025","unstructured":"Geyer, C. E. et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N. Engl. J. Med. 392, 249\u2013257 (2025).","journal-title":"N. Engl. J. Med."},{"key":"65599_CR39","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1200\/JCO.23.02505","volume":"42","author":"S Loibl","year":"2024","unstructured":"Loibl, S. et al. Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2\u2013positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update. J. Clin. Oncol. 42, 3643\u20133651 (2024).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR40","doi-asserted-by":"crossref","unstructured":"Loibl, S. et al. LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years median follow-up. In ESMO Open 10, (ESMO Breast 2025).","DOI":"10.1016\/j.esmoop.2025.105112"},{"key":"65599_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jnci\/djad179","volume":"116","author":"MV Dieci","year":"2023","unstructured":"Dieci, M. V. et al. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer. JNCI: J. Natl Cancer Inst. 116, 69\u201380 (2023).","journal-title":"JNCI: J. Natl Cancer Inst."},{"key":"65599_CR42","doi-asserted-by":"crossref","unstructured":"Javierre, G. V. et al. 1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer. ESMO Open 9, 103011 (2024).","DOI":"10.1016\/j.esmoop.2024.103011"},{"key":"65599_CR43","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1007\/s12094-024-03409-4","volume":"26","author":"O Mart\u00ednez-S\u00e1ez","year":"2024","unstructured":"Mart\u00ednez-S\u00e1ez, O. et al. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey. Clin. Transl. Oncol. 26, 2060\u20132069 (2024).","journal-title":"Clin. Transl. Oncol."},{"key":"65599_CR44","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre, F. et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J. Clin. Oncol. 40, 1816\u20131837 (2022).","journal-title":"J. Clin. Oncol."},{"key":"65599_CR45","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","volume":"27","author":"MV Dieci","year":"2016","unstructured":"Dieci, M. V. et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann. Oncol. 27, 1867\u20131873 (2016).","journal-title":"Ann. Oncol."},{"key":"65599_CR46","unstructured":"World Health Organization. Life Expectancy and Healthy Life Expectancy (World Health Organization, 2025)."},{"key":"65599_CR47","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/ijc.33232","volume":"148","author":"S Pilleron","year":"2021","unstructured":"Pilleron, S. et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int. J. Cancer 148, 601\u2013608 (2021).","journal-title":"Int. J. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65599-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:03:43Z","timestamp":1762250623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65599-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65599"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65599-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.V. has received speaker fees from MSD, Pfizer, GSK and Pierre Fabre, has held an advisory role with AstraZeneca, and received consultant fees from Reveal Genomics. AV reports personal fees from Bayer, Bristol Myers Squibb, Guardant Health, Merck, Novartis, Roche, and Incyte, outside the submitted work. F.B.M. has a patent PCT\/EP2021\/070788 (In vitro method for the prognosis of patients suffering from her2-positive breast cancer) licensed to Reveal Genomics. J.S.P., C.M.P. and A.P. are equity stockholders and consultants of Reveal Genomics. L.P. has a patent WO2018\/103834 (Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy) licensed to Reveal Genomics. A.P. reports grants from Reveal Genomics during the conduct of the study, personal fees from Roche, and grants and personal fees from AstraZeneca, Daiichi Sankyo, and Novartis, outside the submitted work; in addition, A.P. has patent WO2018\/103834 (Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy), PCT\/EP2021\/070788 (In vitro method for the prognosis of patients suffering from her2-positive breast cancer) licensed to Reveal Genomics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9585"}}